Vous êtes sur la page 1sur 28

Registrar Corp

144 Research Drive


Hampton, VA 23666 USA
Phone: +1-757-224-0177
Fax: +1-757-224-0179
info@registrarcorp.com

http://www.registrarcorp.com/fda-drugs/api/registration.jsp?lang=es
Registrar Corp asiste a las compaas con el cumplimiento de la U.S. FDA. Los
Certificados de Registro emitidos por Registrar Corp confirman que a la industria que
usted est cumpliendo con el requisito de registro con la U.S. FDA. La U.S. FDA no
emite o reconoce Certificados de Registro. Registrar Corp no esta afiliada con la U.S.
Food and Drug Administration.

Regulaciones para Medicamentos de U.S. FDA


La U.S. FDA regula los productos de frmacos destinados a ser utilizados en el
diagnstico, cura, mitigacin, tratamiento o prevencin de enfermedades y destinados a
afectar la estructura o cualquier funcin del cuerpo de los seres humanos o animales.
Registrar Corp provee asistencia para Registro, Agente de EE.UU., y Cumplimiento
regulatorio para empresas de EE.UU. y extranjeras en la Industria de Frmacos.
Registro y Listado para Nuevos Establecimientos de Medicamentos
Los propietarios u operadores de todos los Establecimientos de Medicamentos dentro
y fuera de Estados Unidos que se dedican a la fabricacin, preparacin, propagacin,
composicin o elaboracin de medicamentos estn obligados a registrarse y presentar
una lista de todos los medicamentos en distribucin comercial a travs del nuevo
Sistema Electronico de Registro de Drogas y Listado de la U.S. FDA (eDRLS). Para
obtener ayuda con las normas de registro de establecimientos de medicamentos y
listados, simplemente haga clic en el Certificado de Registro de Medicamentos que se
muestra a la izquierda.

Regulaciones U.S. FDA Registro de Establecimiento de


Medicamento y Requisitos de Listado
Dueos u operadores de todos los establecimientos de medicamentos, no exentos
bajo la seccin 510(g) de la Ley de Alimentos, Medicamentos y Cosmticos, que estn
relacionados con la manufactura, preparacin, propagacin, combinacin o
procesamiento de un medicamento o medicamentos debe registrar y emitir un listado
de cada medicamento en distribucin commercial.
Manufactura o procesamiento significa la manufactura, preparacin propagacin,
combinacin o procesamiento de un medicamento o medicamentos tal como se utiliza
en la seccin 510 de la Ley y es de elaboracin qumica, fsica, biolgica u otro
procedimiento de cualquier artculo que cumpla la definicin de medicamento en la
seccin 210(g) de la Ley. El trmino incluye manipulacin, muestreo, anlisis o control
de procedimientos aplicados al producto final o a cualquier parte del proceso.
El trmino medicamento significa (A) articulos reconocidos en la Farmacopea Oficial
de los Estados Unidos, la Farmacopea Oficial Homeoptica de los Estados Unidos o en
el Formulario Oficial Nacional o para cualquier complemento de ellos; (B) artculos con
uso intencionado en el diagnstico, cura, mitigacin, tratamiento o prevencin de
enfermedades en hombres u otros animales; (C) artculos (distintos de alimentos)
destinados a afectar la estructura o cualquier funcin del cuerpo de hombres u otros
animales; y (D) artculos destinados para usarse como componentes de cualquier
artculo especificados en las definiciones (A), (B) o (C).
Registrar Corp asiste a las compaas a cumplir con el Registro de Medicamentos U.S.
FDA y los requisitos de listado. Para asistencia U.S. FDA de Medicamentos,
simplemente haga click en la categora U.S. FDA de Medicamentos aplicable a sus
productos medicamentos.

Registro U.S. FDA de Ingredientes Farmacuticos Activos (API) y


Requisitos de Listado
Un Ingrediente Farmacutico Activo es cualquier substancia o mezcla de substancias
con uso intencionado en la manufactura de un producto medicamento y que cuando
es usado en la produccin de este, se convierte en el ingrediente activo del
medicamento. Dichas substancias proporcionan la actividad farmacolgica u otro
efecto directo en el diagnstico, cura, mitigacin, tratamiento o prevencin de
enfermedad o para afectar la estructura o funcin del cuerpo.
Registrar Corp asiste a las compaas con los siguientes requisitos para API:

Registro U.S. FDA de Establecimiento API

Listado U.S. FDA de Medicamento API y emisin de Etiqueta

Obtencin del Nmero DUNS

Revisin de Etiquetado de Medicamentos e Ingredientes


La U.S. FDA ahora requiere que las etiquetas de medicamentos se indexen utilizando
Lenguaje de marcado extensible (XML) en formato de Etiquetado Estructurado de
Productos (SPL). Registrar Corp ayuda a las empresas a modificar su etiquetado de
medicamentos para cumplir con EE.UU. regulaciones de U.S. FDA. Registrar Corp
provee archivos grficos revisados listos para ser impresos o editados, y un informe
que detalla las normas, el cumplimiento de las guas, cartas de advertencia, las
alertas de importacin, y otros documentos de orientacin de la U.S. FDA. Para
conocer como las regulaciones de U.S. FDA sobre etiquetado de medicamentos se
aplican a sus productos, simplemente haga clic en Notice of FDA Action que se
muestra a la izquierda.

U.S. FDA Drug Labeling Requirements


U.S. FDA Drug Labeling Regulations Can Be Complicated
Registrar Corp's team of Regulatory Advisors can provide a Free Assessment of how
these regulations apply to your particular product. Simply click below to provide
information about your products.
Learn if these regulations apply to you >>

The U.S. Federal Food, Drug and Cosmetic Act (FFDCA) defines "labeling" as all labels
and other written, printed, or graphic matter upon any article or any of its containers
or wrappers, or accompanying such article. The term 'accompanying' is interpreted
liberally to mean more than physical association with the product. It extends to
posters, tags, pamphlets, circulars, booklets, brochures, instructions, websites, etc.

Registrar Corp's Drug Labeling and


Ingredient Review service helps
companies determine their drug's likely
classification and compliance with
applicable labeling requirements.
Registrar Corp cross references your
labeling against thousands of pages within
the Code of Federal Regulations as well as
the Federal Register, CDER's Listing of
OTC Active Ingredients, Rulemaking
History for Nonpresciption Products,
Guidance Documents and Warning Letters
issued by U.S. FDA. Registrar Corp's label
review service provides:

A detailed report (typically 30-40


pages) prepared by our team of
regulatory specialists who
scrutinize each element of your
labeling (including inner packaging,
outer packaging, website, etc.).
A print-ready graphic file of your
revised label which incorporates
our recommended changes.
A generous revision policy
providing additional reports and
revisions for the same label within
90 days at no extra cost.

Learn if these regulations apply to you >>

Nuevos Requisitos de Auto identificacin de la FDA


Los operadores de instalaciones que producen medicamentos genricos y APIs de
medicamentos genricos deben presentar informacin de "auto identificacin" ante la
FDA de los Estados Unidos antes del 3 de diciembre de 2012. La ley impone una
nueva cuota de usuario para determinadas empresas identificadas en las
presentaciones de medicamentos genricos, incluidas las Nuevas Aplicaciones
Abreviadas de Medicamentos (ANDA), enmiendas de ANDAs, y Suplementos de
Aprobacin Previa (PAS). No se requerir que todos los establecimientos paguen la
cuota. Los operadores de instalaciones de medicamentos genricos y ciertos sitios y
organizaciones que se identifican en una presentacin de medicamento genrico
deben presentar informacin de auto identificacin a la FDA, a partir de la cual la FDA
determinar qu empresas deben pagar las nuevas tarifas de usuario y en qu
cantidad. Se espera que el programa de tarifas sea publicado por la FDA el 31 de

enero de 2013.

U.S. FDA Self-Identification Requirements


Operators of facilities that produce generic drugs and generic drug APIs must submit
"self-identification" information to FDA between May 1 and June 1 of each year. This
information is required by the Generic Drug User Fee Amendments of 2012 (GDUFA),
passed by Congress in 2012. FDA uses self-identification data to calculate generic
drug user fees. Under GDUFA, if a facility fails to self-identify, the generic drugs it
manufacturers will be deemed misbranded.
For assistance with determining whether your firm is subject to FDA's selfidentification requirements or submitting self-identification information to FDA, simply
complete the fields below. For immediate assistance, click Ayuda en Vivo.

Certificacin por Aditivos Colorantes de Medicamentos y Lotes de Colorantes


de Medicamentos
Un aditivo colorante de medicamentos es cualquier tinte, pigmento, u otra sustancia
que puede dar color a un producto farmacutico. Estos aditivos estn regulados por la
FDA de los Estados Unidos. Para determinar cmo las regulaciones de la FDA para
aditivos colorantes de medicamentos se aplican a sus productos, simplemente haga
clic en el aviso de accin de la FDA que se muestra a la izquierda.

Requerimientos U.S. FDA Aditivos Colorantes


Aditivos Colorantes en alimentos, medicamentos, cosmticos y dispositivos mdicos
requieren de aprobacin por parte de la U.S. FDA. La forma y la frecuencia de
aprobacin depende en particular del Colorante. Para la mayora de los Colorantes, el
proceso apropiado de aprobacin es el U.S. FDA's Color Batch Certification Program,
el cual requiere la aprobacin de cada lote.
Para la Certificacin de Lotes de Colorantes, manufactures proporcionarn a la U.S.
FDA una muestra representativa de cada Lote de Colorante junto con la
documentacin requerida. La U.S. FDA analiza las muestras de Colorante para
asegurar que estos cumplen las especificaciones requeridas para ser Certificados
como Aditivos Colorantes. Para algunos Colorantes, le Certificacin de Lote puede no
ser apropiada.
Registrar Cop ayuda a las compaas a cumplir con los extensos requisitos de la U.S.
FDA para Aditivos Colorante referenciando la informacin de su colorante con las
miles de pginas del Cdigo Federal de Regulaciones as como el Registro Federal,
Base de Datos EAFUS, Notificaciones GRAS, Guas de Etiquetado y Cartas de
Advertencia emitidas por la U.S. FDA. El servicio de Colorantes de Registrar Corp le

ofrece:
Un reporte detallado (generalmente de 15-20 pginas) redactado por nuestro
equipo de Especialistas Regulatorios quienes analizaran detalladamente cada
elemento de qumico de su Aditivo Colorante, su uso intencionado,
restricciones, requisitos de etiquetado y diluyentes permitidos;
Orientacin sobre el protocolo de tratamiento por lote, requisitos sobre los
registros a mantener y recomendaciones sobre mejores prcticas.

Asistencia para la presentacin de la Certificacin del Lote de Colorante con la


U.S. FDA as como tambin los registros y el mantenimiento de estos para
permitir certificaciones rpidas a futuros lotes del mismo colorante.

Registra Corp asiste a compaas a cumplir con los requisitos U.S. FDA para
Aditivos Colorantes
Selecciones una de las siguientes opciones:
Option 1: Solicitar orientacin para un Colorante en particular
Si usted no conoce los requisitos pertinentes para su Colorante en especficos,
haga click en la liga inferior para obtener orientacin.
Conozca como las regulaciones de la U.S. FDA para Colorantes aplican a su
producto >>

Option 2: Presentar una Certificacin de un Lote de Colorante con la U.S.


FDA
Si usted conoce que su Aditivo Colorante requiere una Certificacin de Lote U.S.
FDA, haga click en la liga inferior para obtener asistencia.
Presentar una Certificacin de un Lote de Colorante con la U.S. FDA >>

U.S. FDA Archivo Maestro de Drogas (DMF)

DMF Examples

Un Archivo Maestro de Drogas (DMF) es una sumisin a la U.S. FDA que puede
utilizarse en apoyo de las sumisiones previas a la comercializacin para facilitar
informacin confidencial y detallada sobre las instalaciones, procesos, o artculos
usados en la fabricacin, elaboracin, envasado y almacenamiento de uno o ms
medicamentos. El equipo de especialistas en regulaciones de Registrar Corp
proporciona orientacin sobre los elementos requeridos, formatos y particularidades
de las sumisiones de Drug Master Files. Para asistencia con la sumisin de Drug
Master Files, haga clic en el Certificado de Drug Master File que se muestra a la
izquierda.

U.S. FDA Drug Master File Requirements


Drug companies can submit a Drug Master File (DMF) to the U.S. Food and Drug
Administration (FDA) to provide confidential information about facilities, processes, or
articles. The DMF holder can then authorize others to use the information in support
of a submission to FDA without disclosing the information to anyone other than FDA.
FDA will require all DMF submissions to be in electronic common technical
document (eCTD) format beginning May 5, 2017. Registrar Corp's Regulatory
Specialists will:
File a new DMF with U.S. FDA in eCTD

Update or Amend an existing DMF with U.S. FDA

Convert existing DMFs to eCTD

Serve as your Agent for U.S. FDA Communications

Reactivate inactive DMFs with U.S. FDA and convert them to eCTD

If you would like to file a new Drug Master File (DMF) with U.S. FDA
File a new DMF with U.S. FDA

If you already have a DMF with FDA


Opcin 1:

Convert your DMF to eCTD

Converting an existing DMF to eCTD format may accelerate FDA's NDA/ANDA


review process. FDA NDA/ANDA reviewers will request a paper copy of the DMF
for any information needed that is not in electronic format, thus delaying the
review.
Convert my DMF to eCTD
Opcin 2:

Update your existing DMF with U.S. FDA

Haga click en la Liga de Actualizacin inferior para cualquiera de las siguientes


opciones:
Update or Amend your DMF with U.S. FDA
File an Annual Report with U.S. FDA

Reactivate a DMF with U.S. FDA

Deactivate a DMF with U.S. FDA


Update your DMF Information with U.S. FDA

Certificado de Registro expedido por Registrar Corp


Empresas registradas con la U.S. FDA son a menudo requeridas por sus clientes y
proveedores de verificar su registro U.S. FDA. Un Certificado de Registro expedido por
Registrar Corp sirve como una verificacin de terceros de su registro U.S. FDA. Para
obtener ms informacin, haga clic en el certificado de Medicamentos que se muestra
a la izquierda.

Drug Certificate of U.S. FDA Registration


Complete the form below to receive a Drug Certificate of Registration issued by
Registrar Corp:
Asistencia con Detenciones Sin Examen Fsico ("DWPE")
Las compaas que exportan productos a los Estados Unidos pueden encontrar sus
envos sometidos a una "detencin sin examen fsico" por la FDA de EE.UU.. Los
productos sujetos a detencin sin examen fsico son retenidos en el puerto de
entrada, mientras que la FDA realiza escrutinios, pruebas y anlisis adicionales. Los
retrasos por estas detenciones pueden resultar largos para las empresas deseosas de
entregar productos a tiempo. Para obtener ayuda con una detencin, simplemente
haga clic en el Aviso de Accin que se muestra a la izquierda.

U.S. FDA Import Regulations


The Food and Drug Administration's (FDA's) mission is to enforce the Federal Food,
Drug, and Cosmetic (FD&C) Act and other laws which are designed to protect
consumers' health and safety.
With the exception of most meat and poultry, all food, drugs, biologics, cosmetics,
medical devices, and electronic products that emit radiation are subject to examination
by FDA when they are being imported into the United States. Most meat and poultry
products are regulated by the U.S. Department of Agriculture.
All imported products are required to meet the same standards as domestic goods.
Imported foods must be pure, wholesome, safe to eat, and produced under sanitary
conditions; drugs and devices must be safe and effective; cosmetics must be safe for
their intended use; radiation-emitting devices must meet established standards; and all
products must contain informative and truthful labeling in English.
FDA Compliance Officers at every U.S. Port of Entry review shipments to prevent non-

compliant products from entering the U.S. market. When detentions occur, Registrar
Corp can help you try to resolve the detention favorably and fast.

Obtain Immediate Assistance with FDA Detentions


Registrar Corp's team of Regulatory Specialists provides immediate detention assistance
for companies with products detained at the port of entry by the FDA. Simply click below
to receive assistance with FDA detentions.
Learn more about FDA Detentions
If you find your shipments detained due to an Import Alert, there are procedures by
which you may petition FDA to be removed from a Red List or added to a Green List.
Registrar Corp provides assistance with this complicated petitioning process.
Learn more about FDA Import Alerts

TITLE 21--FOOD AND DRUGS


CHAPTER I--FOOD AND DRUG ADMINISTRATION
DEPARTMENT OF HEALTH AND HUMAN SERVICES
SUBCHAPTER C--DRUGS: GENERAL
PART 207 REGISTRATION OF PRODUCERS OF DRUGS AND LISTING OF DRUGS IN
COMMERCIAL DISTRIBUTION
Subpart A--General
Sec. 207.3 Definitions.
(a) The following definitions apply to this part:
(1) Act means the Federal Food, Drug, and Cosmetic Act approved June 25, 1938 (52
Stat. 1040 et seq., as amended (21 U.S.C. 301-392)), except as otherwise provided.
(2) Advertising and labeling include the promotional material described in 202.1(l) (1)
and (2) respectively.
(3) Any material change includes but is not limited to any change in the name of the
drug, any change in the identity or quantity of the active ingredient(s), any change in
the identity or quantity of the inactive ingredient(s) where quantitative listing of all
ingredients is required by 207.31(a)(2), any significant change in the labeling of a

prescription drug, and any significant change in the label or package insert of an overthe-counter drug. Changes that are not significant include changes in arrangement or
printing or changes of an editorial nature.
(4) Bulk drug substance means any substance that is represented for use in a drug and
that, when used in the manufacturing, processing, or packaging of a drug, becomes an
active ingredient or a finished dosage form of the drug, but the term does not include
intermediates used in the synthesis of such substances.
(5) Commercial distribution means any distribution of a human drug except for
investigational use under part 312 of this chapter, and any distribution of an animal
drug or animal feed bearing or containing an animal drug for noninvestigational uses,
but the term does not include internal or interplant transfer of a bulk drug substance
between registered establishments within the same parent, subsidiary, and/or affiliate
company. For foreign establishments, the term "commercial distribution" shall have the
same meaning except that the term shall not include distribution of any drug that is
neither imported nor offered for import into the United States.
(6) Drug product salvaging means the act of segregating drug products that may have
been subjected to improper storage conditions, such as extremes in temperature,
humidity, smoke, fumes, pressure, age, or radiation, for the purpose of returning some
or all of the products to the marketplace.
(7) Establishment means a place of business under one management at one general
physical location. The term includes, among others, independent laboratories that
engage in control activities for a registered drug establishment (e.g.,consulting
laboratories), manufacturers of medicated feeds and of vitamin products that are drugs
in accordance with section 201(g) of the act, human blood donor centers, and animal
facilities used for the production or control testing of licensed biologicals, and
establishments engaged in drug product salvaging.
(8) Manufacturing or processing means themanufacture, preparation, propagation,
compounding, or processing of a drug or drugs as used in section 510 of the act and is
the making by chemical, physical, biological, or other procedures of any articles that
meet the definition of drugs in section 201(g) of the act. The term includes
manipulation, sampling, testing, or control procedures applied to the final product or to
any part of the process. The term also includes repackaging or otherwise changing the
container, wrapper, or labeling of any drug package to further the distribution of the
drug from the original place of manufacture to the person who makes final delivery or
sale to the ultimate consumer.
(9) Representative sampling of advertisements means typical advertising material
(excluding labeling as determined in 202.1(l) (1) and (2)) that gives a balanced picture
of the promotional claims used for the drug, e.g., if more than one medical journal

advertisement is used but the promotional content is essentially identical, only one
need be submitted.
(10) Representative sampling of any other labeling means typical labeling material
(excluding labels and package inserts) that gives a balanced picture of the promotional
claims used for the drug, e.g., if more than one brochure is used but the promotional
content is essentially identical, only one need be submitted.
(11) United States agent means a person residing or maintaining a place of business in
the United States whom a foreign establishment designates as its agent. This definition
excludes mailboxes, answering machines or services, or other places where an
individual acting as the foreign establishment's agent is not physically present.
(b) The definitions and interpretations of terms in sections 201, 502(e), and 510 of the
act apply to the use of terms in this part.
[45 FR 38043, June 6, 1980, as amended at 55 FR 11576, Mar. 29, 1990; 66 FR 59156,
Nov. 27, 2001]
Sec. 207.7 Establishment registration and product listing for human blood and blood
products and for medical devices.
(a) Owners and operators of human blood and blood product establishments shall
register and list their products with the Center for Biologics Evaluation and Research
(HFM-375), 1401 Rockville Pike, suite 200N, Rockville, MD 20852-1448, on Form FDA2830 (Blood Establishment Registration and Product Listing), in accordance with part
607 of this chapter. Such owners and operators who also manufacture or process other
drug products at the same establishment shall, in addition, register and list all such
other drug products with the Drug Listing Branch in accordance with this part.
(b) [Reserved]
(c) Owners and operators of establishments engaged in manufacture or processing of
medical devices shall register and list their products with the Center for Devices and
Radiological Health, FDA, on Form FDA-2891 (Initial Registration of Device
Establishments), FDA-2891a (Registration of Device Establishment), and FDA-2892
(Medical Device Listing), in accordance with part 807.
(d) Owners and operators of establishments engaged in the manufacture or processing
at the same establishment of both drug products and medical devices shall (1) register
with the Records Repository Team (HFD-143), Center for Drug Evaluation and Research,
FDA, and list their drug products in accordance with this part, and (2) register with the
Center for Devices and Radiological Health and list their medical devices in accordance
with part 807.

[45 FR 38043, June 6, 1980, as amended at 50 FR 8995, Mar. 6, 1985; 55 FR 11576,


Mar. 29, 1990; 66 FR 59156, Nov. 27, 2001; 69 FR 48775, Aug. 11, 2004]
Subpart B--Exemptions
Sec. 207.10 Exemptions for establishments.
The following classes of persons are exempt from registration and drug listing in
accordance with this part under section 510(g)(1), (g)(2), and (g)(3) of the act, or
because FDA has found, under section 510(g)(5) of the act, that their registration is not
necessary for the protection of the public health. The exemptions in paragraphs (a) and
(b) of this section are limited to pharmacies, hospitals, clinics, and public health
agencies located in any State as defined in section 201(a)(1) of the act.
(a) Pharmacies that operate under applicable local laws regulating dispensing of
prescription drugs and that do not manufacture or process drugs for sale other than in
the regular course of the practice of the profession of pharmacy, including dispensing
and selling drugs at retail. The supplying of prescription drugs by these pharmacies to a
practitioner licensed to administer these drugs for his or her use in the course of
professional practice or to other pharmacies to meet temporary inventory shortages are
not acts that require pharmacies to register.
(b) Hospitals, clinics, and public health agencies that maintain establishments in
conformance with any applicable local laws regulating the practices of pharmacy or
medicine and that regularly engage in dispensing prescription drugs, other than human
blood or blood products, upon prescription of practitioners licensed by law to administer
these drugs to patients under their professional care.
(c) Practitioners who are licensed by law to prescribe or administer drugs and who
manufacture or process drugs solely for use in their professional practice.
(d) Persons who manufacture or process drugs not for sale but solely for use in
research, teaching, or chemical analysis.
(e) Manufacturers of harmless inactive ingredients that are excipients, colorings,
flavorings, emulsifiers, lubricants, preservatives, or solvents that become components
of drugs, and who otherwise would not be required to register under this part.
(f) Persons who only manufacture the following:
(1) Type B or Type C medicated feed using Category I, Type A medicated articles or
Category I, Type B or Type C medicated feeds, and/or;
(2) Type B or Type C medicated feed using Category II, Type B or Type C medicated
feeds.

(3) Persons who manufacture free-choice feeds, as defined in 510.455 of this chapter,
or medicated liquid feeds, as defined in 558.5 of this chapter, where a medicated feed
mill license is required are not exempt.
(g) Any manufacturer of a virus, serum, toxin, or analogous product intended for
treatment of domestic animals who holds an unsuspended and unrevoked license issued
by the Secretary of Agriculture under the animal virus-serum-toxin law of March 4,
1913 (37 Stat. 832 (21 U.S.C. 151et seq. )), provided that this exemption from
registration applies only to the manufacture or processing of that animal virus, serum,
toxin, or analogous product.
(h) Carriers, in their receipt, carriage, holding, or delivery of drugs in the usual course
of business as carriers.
[45 FR 38043, June 6, 1980, as amended at 51 FR 7389, Mar. 3, 1986; 64 FR 63203,
Nov. 19, 1999; 66 FR 59156, Nov. 27, 2001]
Subpart C--Procedures for Domestic Drug Establishments
Sec. 207.20 Who must register and submit a drug list.
(a) Owners or operators of all drug establishments, not exempt under section 510(g) of
the act or subpart B of this part 207, that engage in the manufacture, preparation,
propagation, compounding, or processing of a drug or drugs shall register and submit a
list of every drug in commercial distribution (except that registration and listing
information may be submitted by the parent, subsidiary, and/or affiliate company for all
establishments when operations are conducted at more than one establishment and
there exists joint ownership and control among all the establishments). Drug listing is
not required for the manufacturing, preparation, propagation, compounding, or
processing of an animal feed bearing or containing an animal drug (i.e., a Type B or
Type C medicated feed), nor is drug listing required for establishments engaged in drug
product salvaging. Drug products manufactured, prepared, propagated, compounded,
or processed in any State as defined in section 201(a)(1) of the act must be listed
whether or not the output of such establishments or any particular drug so listed enters
interstate commerce. No owner or operator may register an establishment if any part of
the establishment is registered by any other owner or operator.
(b) Owners or operators of establishments not otherwise required to register under
section 510 of the act that distribute under their own label or trade name a drug
manufactured or processed by a registered establishment may elect to submit listing
information directly to FDA and to obtain a Labeler Code. A distributor who submits
drug listing information shall include theregistration number of the drug establishment
that manufactured, prepared, propagated, compounded, or processed each drug listed.
All distributors who submit drug listing information to FDA assume full responsibility for

compliance with all of the requirements of this part. Each such distributor at the time of
submitting or updating drug listing information as required under 207.30 shall certify to
the registered establishment that the submission has been made by providing a signed
copy of Form FDA-2656 (Registration of Drug Establishment) to the registered
establishment that manufactures or processes the drug. Each such distributor shall
submit the original of Form FDA-2656 showing this certification to FDA, and shall
accompany the certification with a list showing the National Drug Code number that the
distributor has assigned to each drug product. If a distributor does not elect to submit
drug listing information directly to FDA and to obtain a Labeler Code, the registered
establishment shall submit the drug listing information. Distributors or registered
establishments shall use Form FDA-2658 (Registered Establishments' Report of Private
Label Distributors) to submit drug listing information or to request a Labeler Code, or
both.
(c) Before beginning manufacture or processing of a drug subject to one of the
following applications, an owner or operator of an establishment is required to register
before the agency approves or grants it: A new drug application, an abbreviated new
drug application, a new animal drug application, an abbreviated new animal drug
application, a medicated feed mill license application, a biologics license application, or
a request for addition to the index.
(d) No registration fee is required.
(e) Registration and listing do not constitute an admission, or agreement, or
determination that a product is a drug as defined in section 201(g) of the act.
(f) Owners and operators of establishments or persons engaged in the recovery,
screening, testing, processing, storage, or distribution of human cells, tissues, and
cellular and tissue-based products, as defined in 1271.3(d) of this chapter, that are
regulated under section 351 of the Public Health Service Act and/or the Federal Food,
Drug, and Cosmetic Act must register and list those human cells, tissues, and cellular
and tissue-based products with the Center for Biologics Evaluation and Research on
Form FDA 3356 following the procedures set out in subpart B of part 1271 of this
chapter, instead of the procedures for registration and listing contained in this part,
except that the additional listing information requirements in 207.31 remain applicable.
[45 FR 38043, June 6, 1980, as amended at 45 FR 32293, May 16, 1980; 52 FR 2682,
Jan. 26, 1987; 55 FR 11576, Mar. 29, 1990; 64 FR 400, Jan. 5, 1999; 64 FR 56448,
Oct. 20, 1999; 64 FR 63203, Nov. 19, 1999; 66 FR 5466, Jan. 19, 2001; 66 FR 59157,
Nov. 27, 2001; 66 FR 5447, Jan. 19, 2001; 72 FR 69120, Dec. 6, 2007]
Sec. 207.21 Times for registration and drug listing.
(a) The owner or operator of an establishment entering into the manufacture or

processing of a drug or drugs shall register the establishment within 5 days after the
beginning of the operation and shall submit a list of every drug in commercial
distribution at that time. If the owner or operator of the establishment has not
previously entered into such an operation, the owner or operator shall register within 5
days after submitting a new drug application, abbreviated new drug application, new
animal drug application, abbreviated new animal drug application, request for addition
to the index, medicated feed mill license application, or a biologics license application.
Owners or operators shall renew their registration information annually.
The schedule is as follows:
First letter of company name Date FDA will mail forms
A or B January
C, D, or E February
F, G, or H March
I, J, K, L. or M April
N, O, P, Q, or R May
S or T June
U, V, W, X, Y, or Z July
(b) Owners and operators of all registered establishments shall update their drug listing
information every June and December.
[45 FR 38043, June 6, 1980, as amended at 55 FR 11576, Mar. 29, 1990; 64 FR 400,
Jan. 5, 1999; 64 FR 56448, Oct. 20, 1999; 64 FR 63203, Nov. 19, 1999; 66 FR 59157,
Nov. 27, 2001; 72 FR 69120, Dec. 6, 2007]
Sec. 207.22 How and where to register and list drugs.
(a) An establishment shall register the first time on Form FDA-2656 (Registration of
Drug Establishment), obtainable on request from the Records Repository Team (HFD143), Center for Drug Evaluation and Research, Food and Drug Administration, 5600
Fishers Lane, Rockville, MD 20857, or from FDA district offices. An establishment whose
drug registration for that year was validated under 207.35 shall make subsequent
annual registration on Form FDA-2656 as described in 207.21(a) by mailing the
completed form to the above address within 30 days after receipt from FDA.
(b) The first list of drugs and later June and December updatings shall be on Form FDA2657 (Drug Product Listing), obtainable upon request as described in paragraph (a) of
this section. An establishment may submit, in lieu of Form FDA-2657, tapes for
computer inputs containing the information specified in Form FDA-2657 if formats
proposed for this use were reviewed and approved by the Records Repository Team
(HFD-143), Center for Drug Evaluation and Research, FDA.
[45 FR 38043, June 6, 1980, as amended at 50 FR 8995, Mar. 6, 1985; 55 FR 11576,
Mar. 29, 1990; 69 FR 48775, Aug. 11, 2004]

Sec. 207.25 Information required in registration and drug listing.


(a) Form FDA-2656 (Registration of Drug Establishment) provides for furnishing or
confirming information required by the act. This information includes, for each
establishment, the name and full address of the drug establishment; all trade names
used by the establishment; the kind of ownership or operation (that is, individually
owned, partnership or corporation); and the name of the owner or operator of the
establishment. The termname of the owner or operator includes in the case of a
partnership the name of each partner, and in the case of a corporation the name and
title of each corporate officer and director and the name of the State of incorporation.
(b) Form FDA-2657 (Drug Product Listing) provides that information required by the act
be furnished as follows:
(1) A list of drugs, including bulk drug substances and Type A articles for use in the
manufacture of animal feeds as well as finished dosage forms, by established name and
by proprietary name, that are being manufactured or processed for commercial
distribution and that have not been included in any list previously submitted to FDA on
Form FDA-2657 or in conjunction with the FDA voluntary inventory on Form FDA-2422
(Survey Report of Marketed Drugs), or Form FDA-2250 (National Drug Code Directory
Input).
(2) For each drug listed that the registrant regards as subject to section 505 or 512 of
the act, the new drug application number, abbreviated new drug application number,
new animal drug application number, or abbreviated new animal drug application
number and a copy of all current labeling, except that only one representative container
or carton label need be submitted where differences exist only in the quantity of
contents statement.
(3) For each drug listed that the registrant regards as subject to section 351 of the
Public Health Service Act, the license number of the manufacturer.
(4) For each human prescription drug listed that the registrant regards as not subject to
section 505 of the act or 351 of the Public Health Service Act, and that is not
manufactured by a registered blood bank, a copy of all current labeling (except that
only one representative container or carton label need be submitted where differences
exist only in the quantity of contents statement) and a representative sampling of
advertisements.
(5) For each human over-the-counter drug listed, or each animal drug listed, that the
registrant regards as not subject to section 505 or 512 of the act or 351 of the Public
Health Service Act, a copy of the label (except that only one representative container or
carton label need be submitted where differences exist only in the quantity of contents

statement), the package insert, and a representative sampling of any other labeling.
(6) For each prescription or over-the-counter drug so listed that the registrant regards
as not subject to section 505 or 512 of the act or 351 of the Public Health Service Act,
and that is not manufactured by a registered blood bank, a quantitative listing of the
active ingredient(s). Unless the quantitative listing is expressed as a percentage in the
offical compendium or the ingredient is a nonantibiotic ingredient in a Type A medicated
article for use in the manufacture of animal feeds, the quantity of an ingredient shall be
expressed in terms of the amount, not the percent, of that ingredient in each dosage
unit or, if the drug is not in unit dosage form, the amount of the ingredient in a specific
unit of weight or measure of the drug. For a drug formulation that is a Type A
medicated article subject to 207.35(b)(2)(iii), the registrant may limit the quantitative
listing of ingredients to each variation of level of active drug ingredient.
(7) For each drug listed, the registration number of every drug establishment within the
parent company at which it is manufactured or processed.
(8) For each drug listed, the National Drug Code (NDC) number. If FDA has not
assigned an NDC Labeler Code, the registrant shall include a Product Code and Package
Code and FDA will assign a Labeler Code as described in 207.35(b)(2)(i).
(c) For each drug product listed that is subject to the imprinting requirements of part
206 of this chapter, including products that are exempted under 206.7(b), drug
companies must submit a document that provides the name of the product, its active
ingredient(s), dosage strength, National Drug Code number, the name of its
manufacturer or distributor, its size, shape, color, and code imprint (if any), and any
other characteristic that identifies the product as unique.
[45 FR 38043, June 6, 1980, as amended at 52 FR 2682, Jan. 26, 1987; 55 FR 11577,
Mar. 29, 1990; 58 FR 47959, Sept. 13, 1993; 63 FR 26698, May 13, 1998; 64 FR 400,
Jan. 5, 1999; 66 FR 59157, Nov. 27, 2001]
Sec. 207.26 Amendments to registration.
Changes in individual ownership, corporate or partnership structure location or drughandling activity, shall be submitted by Form FDA-2656 (Registration of Drug
Establishment) as amendment to registration within 5 days of such changes. A change
in a registered establishment's firm name within 6 months of the registration of the
establishment is required to be supported by a signed statement of the establishment's
owner or operator that the change is not made for the purpose of changing the name of
the manufacturer of a drug product under 201.1 of this chapter. Changes in the names
of officers and directors of the corporations do not require such amendment but must
be shown at time of annual registration.

[45 FR 25777, Apr. 15, 1980, as amended at 55 FR 11577, Mar. 29, 1990]
Sec. 207.30 Updating drug listing information.
(a) After submitting the initial drug listing information, every person who is required to
list drugs under 207.20 shall submit on Form FDA-2657 (Drug Product Listing) during
each subsequent June and December, or at the discretion of the registrant when the
change occurs, the following information:
(1) A list of each drug introduced by the registrant for commerical distribution which
has not been included in any list previously submitted. The registrant shall provide all of
the information required by 207.25(b) for each such drug.
(2) A list of each drug formerly listed in accordance with 207.25(b) for which
commercial distribution has been discontinued, including for each drug so listed the
National Drug Code (NDC) number, the identity by established name and by proprietary
name, and date of discontinuance. It is requested but not required that the reason for
discontinuance of distribution be included with this information.
(3) A list of each drug for which a notice of discontinuance was submitted under
paragraph (a)(2) of this section and for which commercial distribution has been
resumed, including for each drug so listed the NDC number, the identity by established
name and by proprietary name, the date of resumption, and any other information
required by 207.25(b) not previously submitted.
(4) Any material change in any information previously submitted.
(b) When no changes have occurred since the previously submitted list, no report is
required.
Sec. 207.31 Additional drug listing information.
(a) In addition to the information routinely required by 207.25 and 207.30, FDA may
require submission of the following information by letter or byFederal Registernotice:
(1) For a particular prescription drug so listed that the registrant regards as not subject
to section 505 of the act, upon request by FDA for good cause, a copy of all
advertisements.
(2) For a particular drug product so listed that the registrant regards as not subject to
section 505 or 512 of the act, upon a finding by FDA that it is necessary to carry out
the purposes of the act, a quantitative listing of all ingredients.
(3) For a particular drug product, upon request by FDA, a brief statement of the basis

for the registrant's belief that the drug product is not subject to section 505 or 512 of
the act.
(4) For each registrant, upon a finding by FDA that it is necessary to carry out the
purposes of the act, a list of each listed drug product containing a particular ingredient.
(b) It is requested but not required that a qualitative listing of the inactive ingredients
be submitted for all listed drugs in the format prescribed in Form FDA-2657 (Drug
Product Listing).
(c) It is requested but not required that a quantitative listing of the active ingredients
be submitted for all drugs listed that are subject to section 505 or 512 of the act or
section 351 of the Public Health Service Act.
[45 FR 38043, June 6, 1980, as amended at 63 FR 26698, May 13, 1998; 64 FR 400,
Jan. 5, 1999]
Sec. 207.35 Notification of registrant; drug establishment registration number and drug
listing number.
(a) FDA will provide to the registrant a validated copy of Form FDA-2656 (Registration
of Drug Establishment) as evidence of registration. This validated copy will be sent to
the mailing address shown on the form. FDA will assign a permanent registration
number to each drug establishment registered in accordance with these regulations.
(b) Using the National Drug Code (NDC) numbering system, FDA assigns a drug listing
number to each drug or class of drugs listed as follows:
(1) If a drug is already listed in the National Drug Code System or in the National
Health Related Items Code System, the number is the same as that assigned under
those codes. FDA adds a lead zero to the first three characters of the code, which
identifies the manufacturer or distributor, to expand the "Labeler Code" segment to four
characters. The National Drug Code, Product Code, and Package Code configurations
used to describe these drugs, or any drugs added to the product line, remain the same,
i.e., a four-character Product Code and a two-character Package Code. A manufacturer
or distributor may either retain alphanumeric characters that are already used in the
Product Code and Package Code segments of the National Drug Code or convert these
alphanumeric characters to all numeric digits. The manufacturer or distributor shall
inform FDA of a decision to convert the alphanumeric characters to all numeric digits.
(2) If a registered establishment or distributor has not previously participated in the
National Drug Code System or in the National Health Related Items Code System, FDA
uses the National Drug Code numbering system in assigning a number, as follows (only
numerals are used):

(i) The first 5 numeric characters of the 10-character code identify the manufacturer or
distributor and are known as the Labeler Code. FDA will expand the Labeler Code from
five to six numeric characters when the available five-character code combinations are
exhausted. FDA will assign Labeler Code numbers and provide them to the registrant
along with the validated copy of Form FDA-2656. Any registered firm that does not
have an assigned Labeler Code will be assigned one when registration and listing
information are submitted.
(ii) The last 5 numeric characters of the 10-character code identify the drug and the
trade package size and type. The segment that identifies the drug formulation is known
as the Product Code and the segment that identifies the trade package size and type is
known as the Package Code. The manufacturer or distributor will assign the Product
Code and the Package Code before drug listing and include these codes in Form FDA2657 (Drug Product Listing). The manufacturer or distributor may use either of two
methods in assigning the Product and Package Codes: a 3-2 Product-Package Code
configuration (e.g., 542-12) or a 4-1 Product-Package Code configuration (e.g., 54212). A manufacturer or distributor with a given Labeler Code shall use only one such
Product-Package Code configuration and shall use this same configuration in assigning
the Product-Package Codes for all drugs included in the drug listing. The manufacturer
or distributor shall report to FDA the Product-Package Code configuration used in
assigning these codes.
(iii) If the drug formulation is a Type A medicated article intended for use in the
manufacture of an animal feed, FDA assigns a separate Product Code only for each
variation of level of active drug ingredient.
(3) FDA requests but does not require that the NDC number appear on all drug labels
and in other drug labeling, including the label of any prescription drug container
furnished to a consumer. If the NDC number is shown on a drug label, it shall be placed
as follows:
(i) The NDC number shall appear prominently in the top third of the principal display
panel of the label on the immediate container and of any outside container or wrapper.
Instead of appearing in the top third of the label, the NDC number may appear as part
of and contiguous to any bar-code symbol for any drug product if two conditions are
met. First, the symbol appears prominently on the immediate container and on any
outside container or wrapper and in a conspicuous location; this condition is not
satisfied by the appearance of the symbol only on the natural bottom of a container or
wrapper. Second, the bar-code symbol is compatible with the NDC, i.e., the symbol
provides a format capable of encoding the numeric characters of an NDC Number. The
termprincipal display panel, as used in this paragraph, means that part of a label most
likely to be displayed, presented, shown, or examined under customary conditions of
display to the consumer (for over-the-counter drug products) or to the dispenser (for

prescription drug products).


(ii) The NDC number shall be preceded by the prefix "NDC" or "N" when it is used on a
label or in labeling. The prefix used for a drug product shall be used consistently on the
label of the immediate container, outside container, or wrapper, if any, and on other
labeling for that drug product.
(iii) The Product-Package Code configuration shall be indicated and the segments of the
number shall be separated by a dash, e.g., NDC 15643-542-12 or N 15643-542-12.
(iv) All 10 characters shall appear and the leading zeros in any segment of the NDC
number shall be shown, except that leading zeros may be omitted from any segment of
the NDC number when the NDC number is used for product identification by direct
imprinting on dosage forms or in the case of containers too small or otherwise unable to
accommodate a label with sufficent space to bear both required and optional labeling
information.
(v) The placing of the assigned NDC number on a label or in other labeling does not
require the submission of a supplemental new drug application, supplemental new
animal drug application, or a modification to an index listing.
(4)(i) If any change occurs in those product characteristics that clearly distinguish one
drug product version from another, the registrant shall assign a new NDC number to the
new product version and submit that information to FDA. Such a change includes, but is
not limited to, a change in active ingredient(s); strength or concentration of active
ingredient(s); dosage form; route of administration, if it also includes a change in
product formulation; product name; and a change in marketing status from prescription
to over-the-counter or over-the-counter to prescription. If, by notice in theFederal
Register,FDA requires a change in drug product characteristics and determines the
change will require assignment of a new product code to the reformulated product, FDA
will announce its determination in theFederal Registerpublication that requires the
change, setting forth its reasoning and justification for its determination. If a change
only in the trade package is involved, the registrant may revise the trade package code
without the assignment of a new product code segment, but shall inform FDA of the
new code for the trade package and the characteristics of the new trade package.
(ii) When a registrant has discontinued a drug product, its product code may be
reassigned to another drug product 5 years after the expiration date of the discontinued
product, or, if there is no expiration date, 5 years after the last shipment of the
discontinued product into commercial distribution. Reuse of product codes may occur,
under the specified conditions, regardless of the NDC, Product Code, and Package Code
configuration used.
(c) Although registration and drug listing are required to engage in the drug activities

described in 207.20, validation of registration and the assignment of a drug listing


number do not, in themselves, establish that the holder of the registration is legally
qualified to deal in such drugs.
[45 FR 38043, June 6, 1980, as amended at 48 FR 54007, Nov. 30, 1983; 52 FR 2682,
Jan. 26, 1987; 55 FR 11577, Mar. 29, 1990; 64 FR 400, Jan. 5, 1999; 72 FR 69120,
Dec. 6, 2007]
Sec. 207.37 Inspection of registrations and drug listings.
(a) A copy of the Form FDA-2656 (Registration of Drug Establishment) filed by the
registrant will be available for inspection in accordance with section 510(f) of the act, at
the Records Repository Team (HFD-143), Center for Drug Evaluation and Research,
Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857. In addition,
copies of these forms for establishments located within a particular geographic area are
available for inspection at FDA district offices responsible for that geographical area.
Copies of forms submitted by foreign drug establishments are available for inspection at
the Division of Manufacturing and Product Quality, Foreign Inspection Team (HFD-325),
Office of Compliance, Center for Drug Evaluation and Research, Food and Drug
Administration, 5600 Fishers Lane, Rockville, MD 20857. Upon request and receipt of a
stamped, self-addressed envelope, the Records Repository Team, the Foreign Inspection
Team, or the appropriate FDA district office will verify registration numbers or provide
the location of a registered establishment. The mailing address for the Foreign
Inspection Team is: Division of Manufacturing and Product Quality, Office of Compliance,
Center for Drug Evaluation and Research (HFD-325), Food and Drug Administration,
5600 Fishers Lane, Rockville, MD 20857.
(1) The following types of information submitted under the drug listing requirements
will be available for public disclosure when compiled:
(i) A list of all drug products.
(ii) A list of all drug products arranged by labeled indications or pharmacological
category.
(iii) A list of all drug products arranged by manufacturer.
(iv) A list of a drug product's active ingredients.
(v) A list of drug products newly marketed or for which marketing is resumed.
(vi) A list of drug products discontinued.
(vii) Labeling.

(viii) Advertising.
(ix) Information that has become a matter of public knowledge.
(x) A list of drug products containing a particular active ingredient.
(xi) A list of all code imprints.
(2) The following types of information submitted in accordance with the drug listing
requirements will not be available for public disclosure (except that any of the
information will be available for public disclosure if it has become a matter of public
knowledge or if FDA finds that confidentiality would be inconsistent with protection of
the public health):
(i) Any information submitted as the basis upon which it has been determined that a
particular drug product is not subject to section 505 or 512 of the act.
(ii) A list of a drug product's inactive ingredients.
(iii) A list of drugs containing a particular inactive ingredient.
(b) Requests for information about registrations and drug listings of an establishment
should be directed to the Information Management Team (HFD-095), Office of
Information Technology, Center for Drug Evaluation and Research, Food and Drug
Administration, 5600 Fishers Lane, Rockville, MD 20857 or, with respect to the
information described in paragraph (a) of this section, to the FDA district office
responsible for the geographic area in which the establishment is located.
[45 FR 38043, June 6, 1980, as amended at 50 FR 8996, Mar. 6, 1985; 55 FR 11577,
Mar. 29, 1990; 58 FR 47959, Sept. 13, 1993; 63 FR 26698, May 13, 1998; 64 FR 400,
Jan. 5, 1999; 66 FR 59157, Nov. 27, 2001; 69 FR 48775, Aug. 11, 2004]
Sec. 207.39 Misbranding by reference to registration or to registration number.
Registration of a drug establishment or drug wholesaler, or assignment of a registration
number, or assignment of a NDC number does not in any way denote approval of the
firm or its products. Any representation that creates an impression of official approval
because of registration or possession of registration number or NDC number is
misleading and constitutes misbranding.
Subpart D--Procedure for Foreign Drug Establishments
Sec. 207.40 Establishment registration and drug listing requirements for foreign

establishments.
(a) Foreign drug establishments whose drugs are imported or offered for import into
the United States shall comply with the establishment registration and drug listing
requirements in subpart C of this part, unless exempt under subpart B of this part or
unless the drugs enter a foreign trade zone and are re-exported from that foreign trade
zone without having entered U. S. commerce.
(b) No drug may be imported or offered for import into the United States unless it is
listed as required in subpart C of this part and manufactured, prepared, propagated,
compounded, or processed at a registered foreign drug establishment; however, this
restriction does not apply to a drug imported or offered for import under the
investigational use provisions in part 312 of this chapter, or the investigational new
animal drug use provisions in part 511 of this chapter, or to a component of a drug
imported under section 801(d)(3) of the act. Foreign drug establishments shall submit
all listing information, including labels and labeling, and registration information in the
English language.
(c) Each foreign drug establishment required to register under paragraph (a) of this
section shall submit the name, address, and phone number of its United States agent
as part of its initial and updated registration information in accordance with subpart C
of this part. Each foreign drug establishment shall designate only one United States
agent.
(1) The United States agent shall reside or maintain a place of business in the United
States.
(2) Upon request from FDA, the United States agent shall assist FDA in communications
with the foreign drug establishment, respond to questions concerning the foreign drug
establishment's products that are imported or offered for import into the United States,
and assist FDA in scheduling inspections of the foreign drug establishment. If the
agency is unable to contact the foreign drug establishment directly or expeditiously,
FDA may provide information or documents to the United States agent, and such an
action shall be considered to be equivalent to providing the same information or
documents to the foreign drug establishment.
(3) The foreign drug establishment or the United States agent shall report changes in
the United States agent's name, address, or phone number to FDA within 10-business
days of the change.
[66 FR 59157, Nov. 27, 2001]

TITLE 21--FOOD AND DRUGS


CHAPTER I--FOOD AND DRUG ADMINISTRATION
DEPARTMENT OF HEALTH AND HUMAN SERVICES
SUBCHAPTER D--DRUGS FOR HUMAN USE
PART 314 -- APPLICATIONS FOR FDA APPROVAL TO MARKET A NEW DRUG
Subpart G--Miscellaneous Provisions
Sec. 314.420 Drug master files.
(a) A drug master file is a submission of information to the Food and Drug
Administration by a person (the drug master file holder) who intends it to be used for
one of the following purposes: To permit the holder to incorporate the information by
reference when the holder submits an investigational new drug application under part
312 or submits an application or an abbreviated application or an amendment or
supplement to them under this part, or to permit the holder to authorize other persons
to rely on the information to support a submission to FDA without the holder having to
disclose the information to the person. FDA ordinarily neither independently reviews
drug master files nor approves or disapproves submissions to a drug master file.
Instead, the agency customarily reviews the information only in the context of an
application under part 312 or this part. A drug master file may contain information of
the kind required for any submission to the agency, including information about the
following:
(1) [Reserved]
(2) Drug substance, drug substance intermediate, and materials used in their
preparation, or drug product;
(3) Packaging materials;
(4) Excipient, colorant, flavor, essence, or materials used in their preparation;
(5) FDA-accepted reference information. (A person wishing to submit information and
supporting data in a drug master file (DMF) that is not covered by Types II through IV
DMF's must first submit a letter of intent to the Drug Master File Staff, Food and Drug
Administration, 5901-B Ammendale Rd., Beltsville, MD 20705-1266.) FDA will then
contact the person to discuss the proposed submission.
(b) An investigational new drug application or an application, abbreviated application,
amendment, or supplement may incorporate by reference all or part of the contents of

any drug master file in support of the submission if the holder authorizes the
incorporation in writing. Each incorporation by reference is required to describe the
incorporated material by name, reference number, volume, and page number of the
drug master file.
(c) A drug master file is required to be submitted in two copies. The agency has
prepared guidance that provides information about how to prepare a well-organized
drug master file. If the drug master file holder adds, changes, or deletes any
information in the file, the holder shall notify in writing, each person authorized to
reference that information. Any addition, change, or deletion of information in a drug
master file (except the list required under paragraph (d) of this section) is required to
be submitted in two copies and to describe by name, reference number, volume, and
page number the information affected in the drug master file.
(d) The drug master file is required to contain a complete list of each person currently
authorized to incorporate by reference any information in the file, identifying by name,
reference number, volume, and page number the information that each person is
authorized to incorporate. If the holder restricts the authorization to particular drug
products, the list is required to include the name of each drug product and the
application number, if known, to which the authorization applies.
(e) The public availability of data and information in a drug master file, including the
availability of data and information in the file to a person authorized to reference the
file, is determined under part 20 and 314.430.
[50 FR 7493, Feb. 22, 1985, as amended at 50 FR 21238, May 23, 1985; 53 FR 33122,
Aug. 30, 1988; 55 FR 28380, July 11, 1990; 65 FR 1780, Jan. 12, 2000; 65 FR 56479,
Sept. 19, 2000; 67 FR 9586, Mar. 4, 2002; 69 FR 13473, Mar. 23, 2004]

Food and Drug Amendments Act of 2007 (Public Law 11085) (FDAAA)
U.S. FDA Drug Labeling: 21 C.F.R. Part 201 Subparts A and
C
U.S. FDA Color Additives: 21 C.F.R. Parts 73, 74, and 80

Registrar Corp Mexico

About Registrar Corp Mexico


The United States and Mexico are close when it comes to trade. In 2013, Mexico was
the United States' third largest supplier of goods imports, and half of U.S. fresh fruit
and vegetable imports came from Mexico. Registrar Corp's Mexico office helps food,
drug, medical device, and cosmetic companies, navigate FDA regulations.
Registrar Corp is a consulting firm that helps companies comply with U.S. Food and
Drug Administration regulations. Founded in 2003, Registrar Corp has expanded to 18
offices worldwide and has assisted over 20,000 companies meet FDA requirements. FDA
regulation services are offered on a fixed-fee basis.
Puebla #282
Col. Roma
Del. Cuauhtemoc
Zip Code: 06700
Mexico, D.F
Phone: +52 (55)-55-14-47-62
Fax: +52 (55)-52-07-91-50
Email: mexico@registrarcorp.com
Registrar Corp's International Locations:

Registrar Corp Australia


Registrar Corp Central

Registrar Corp Japan

Registrar Corp South


Korea

Registrar Corp Malaysia

Registrar Corp Tunisia

Registrar Corp China

Registrar Corp Mexico

Registrar Corp Turkey

Registrar Corp Europe

Registrar Corp Philippines

Registrar Corp India

Registrar Corp South Africa Registrar Corp Vietnam

America

Registrar Corp Israel

Registrar Corp USA


144 Research Drive
Hampton, Virginia 23666
USA
Phone: +1-757-224-0177
Fax: +1-757-224-0179

Registrar Corp South


America

Registrar Corp United


States

Email: info@registrarcorp.com
About Registrar Corp U.S. Office in Hampton, VA
In 2003 Registrar Corp opened its regulatory services firm in Hampton, Virginia to help
businesses with U.S. FDA regulatory compliance.
Import and export industry professionals understand that there are many complex
regulations monitoring all food, drugs and medical devices brought into the United
States to be sold. As these regulations are updated over time, it becomes harder to
know precisely what all those rules are and how to confirm products and facilities are in
compliance. Shipments detained at the border due to non-compliance can cost precious
time and loss of revenue. When this happens, business owners need help fast.
Staffed by multi-lingual professionals with backgrounds in science, industry and
government, our Hampton-based company has served as a reliable consulting resource
for businesses both within the United States and abroad for over 10 years, and grown to
18 international branch offices.
Clients include large multi-nationals, as well as small family-owned businesses in the
U.S. and more than 160 countries around the world. The Hampton headquarters
supports 10 different languages to make communications with its more than 20,000
clients in the food and beverage, drug, medical devices, cosmetic and radiation-emitting
electronic device industries comfortable and easy.